Fumiko Nakazeki; Itaru Tsuge; Takahiro Horie; Keiko Imamura; Kayoko Tsukita; Akitsu Hotta; Osamu Baba; Yasuhide Kuwabara; Tomohiro Nishino; Tetsushi Nakao; Masataka Nishiga; Hitoo Nishi; Yasuhiro Nakashima; Yuya Ide; Satoshi Koyama; Masahiro Kimura; Shuhei Tsuji; Motoko Naitoh; Shigehiko Suzuki; Yuishin Izumi; Toshitaka Kawarai; Ryuji Kaji; Takeshi Kimura; Haruhisa Inoue; Koh Ono
Clin Sci (Lond) (2019) 133 (4): 583–595.
Cover ImageRepresentative immunofluorescent staining of β3-tubulin (green) of SPG4-derived neurons treated LNA-miR-33a for 48 hours. In the latest issue of Clinical Science (volume 133, issue 4), Nakazeki et al. demonstrate through studies on induced pluripotent stem cell-derived cortical neurons that miR-33a is a potential therapeutic target for the treatment of SPG4-related hereditary spastic paraplegia.